Table 1.
Pathogenic variants (positive controls) | Neutral variants (negative controls) | P value | |||
Number of probands | Mean ± standard deviation/percentage | Number of probands | Mean ± standard deviation/percentage | ||
Proband data | |||||
BRCAPRO score alla | 115 | 0.580 ± 0.353 | 38 | 0.381 ± 0.219 | 0.000 |
BRCAPRO1 scorea | 65 | 0.472 ± 0.300 | 20 | 0.293 ± 0.155 | 0.000 |
BRCAPRO2 scorea | 50 | 0.244 ± 0.186 | 18 | 0.163 ± 0.123 | 0.001 |
Myriad II scorea | 115 | 0.241 ± 0.145 | 38 | 0.174 ± 0.094 | 0.000 |
Sex (male)b | 115 | 3.5 | 38 | 0 | 0.000 |
BCb | 115 | 80.9 | 38 | 84.2 | 0.810 |
Bilateral BCb | 115 | 14.8 | 38 | 18.4 | 0.611 |
Age at BC diagnosisc | 93 | 43.419 ± 10.208 | 32 | 46.178 ± 9.591 | 0.008 |
OCb | 115 | 18.3 | 38 | 5.3 | 0.066 |
Age at OC diagnosisc | 21 | 54.381 ± 9.967 | 2 | 48.190 ± 9.899 | 0.108 |
Family data | |||||
Members affectedd | 115 | 3.548 ± 1.640 | 38 | 3.234 ± 1.124 | 0.056 |
Proportion affecteda | 115 | 0.183 ± 0.094 | 38 | 0.173 ± 0.078 | 0.199 |
Number of tumorsd | 115 | 4.200 ± 1.957 | 38 | 3.732 ± 1.329 | 0.007 |
Total BC tumorsd | 115 | 3.400 ± 2.021 | 38 | 3.266 ± 1.277 | 0.422 |
Bilateral BCd | 115 | 0.435 ± 0.637 | 38 | 0.375 ± 0.620 | 0.279 |
BC in malesb | 115 | 10.4 | 38 | 2.6 | 0.820 |
Age at BC diagnosisc | 115 | 45.607 ± 7.951 | 38 | 48.623 ± 7.577 | 0.000 |
Total OC tumorsd | 115 | 0.800 ± 0.929 | 38 | 0.466 ± 0.343 | 0.000 |
Age at OC diagnosisc | 64 | 52.982 ± 10.323 | 5 | 51.091 ± 11.234 | 0.435 |
BC, breast cancer; OC, ovarian cancer. aUnivariate gamma linear regression model (t test). bTwo-by-two table (Fisher's exact test). cUnivariate Gaussian linear regression model (t test). dUnivariate Poisson linear regression model (z test).